M&A Deal Summary

LabCorp Acquires Toxikon

On November 18, 2021, LabCorp acquired life science company Toxikon

Acquisition Highlights
  • This is LabCorp’s 20th transaction in the Life Science sector.
  • This is LabCorp’s 37th transaction in the United States.
  • This is LabCorp’s 4th transaction in Massachusetts.

M&A Deal Summary
Date 2021-11-18
Target Toxikon
Sector Life Science
Buyer(s) LabCorp
Deal Type Add-on Acquisition

Target

Toxikon

Bedford, Massachusetts, United States
Toxikon is a preclinical contract research organization (CRO) providing in vivo, in vitro, and analytical testing services for the pharmaceutical, biotechnology, and medical device industries worldwide, helping those companies gain approval for their products quickly and bring them to market successfully. Toxikon was founded in 1977 and is based in Bedford, Massachusetts.

Search 201,429 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

LabCorp

Burlington, North Carolina, United States
Category Company
Sector Test/Measurement Equipment
Employees67,000
Revenue 12.2B USD (2023)
DESCRIPTION
LabCorp's corporate headquarters in downtown Burlington, North Carolina.
LabCorp's corporate headquarters in downtown Burlington, North Carolina.

LabCorp of America Holdings is a provider of medical laboratory tests and services through a national network of primary clinical laboratories and specialty testing laboratories. LabCorp is based in Burlington, North Carolina.

DEAL STATS #
Overall 39 of 44
Sector (Life Science) 20 of 21
Type (Add-on Acquisition) 27 of 28
State (Massachusetts) 4 of 5
Country (United States) 37 of 42
Year (2021) 3 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-08-12 Ovia Health

Boston, Massachusetts, United States

Ovia Health is a digital health platform used by millions of women seeking information and support with family planning, pregnancy, and parenting. Ovia Health is based in Boston, Massachusetts.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-12-23 PGDx

Baltimore, Maryland, United States

PGDx has empowered the fight against cancer by unlocking actionable information from the genome to drive biomarker-informed treatment plans. The PGDx elio portfolio of tissue-based and liquid biopsy comprehensive genomic solutions enables personalized care for all patients by bringing precision oncology testing to where they are. It was established by researchers from Johns Hopkins University who are pioneers in cancer genome sequencing and liquid biopsy technologies. PGDx was formed in 2010 and is based in Baltimore, Maryland.

Buy $575M
Mergr

Product

Company

Legal